HIF2ɑ Requires Engagement with YAP/TAZ and AP-1 Transcription Factors to Maintain Oncogenic Transcription in Clear Cell Renal Cell Carcinoma [CUT&Tag]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 60 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Kidney cancerThis series is part of our curated briefing on it.
- Samples
- 60 samples: 48 distinct titles, 7 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE295183_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1253665 and SRA study SRP580324. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 60 sample titles: 48 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8943314 cJUN_786O_Parental_1
- GSM8943315 cJUN_786O_shJUN_1
- GSM8943316 cJUN_786O_Parental_2
- GSM8943317 cJUN_786O_shHIF2_2
- GSM8943318 cJUN_786O_Parental_3
- GSM8943319 cJUN_786O_shYT_3
- GSM8943320 cJUN_RCC4_Parental
- GSM8943321 cJUN_A498_Parental
- GSM8943325 H3K27ac_786O_Parental_1
- GSM8943326 H3K27ac_786O_shHIF2_1
- GSM8943327 H3K27ac_786O_Parental_2
- GSM8943328 H3K27ac_786O_shYT_2
- GSM8943329 H3K27ac_A498_Parental
- GSM8943330 H3K27ac_A498_shYT
- GSM8943331 H3K27ac_RCC4_Parental
- GSM8943332 H3K27ac_RCC4_shYT
- GSM8943333 H3K4me3_786O_Parental_1
- GSM8943334 H3K4me3_786O_shHIF2_1
- GSM8943335 H3K4me3_786O_Parental_2
- GSM8943336 H3K4me3_786O_shYT_2
- GSM8943337 H3K4me3_A498_Parental
- GSM8943338 H3K4me3_A498_shYT
- GSM8943339 H3K4me3_RCC4_Parental
- GSM8943340 H3K4me3_RCC4_shYT
- GSM8943341 HIF2a_786O_Parental_1
- GSM8943342 HIF2a_786O_shJUN_1
- GSM8943343 HIF2a_786O_Parental_2
- GSM8943344 HIF2a_786O_shHIF2_2
- GSM8943345 HIF2a_786O_Parental_3
- GSM8943346 HIF2a_786O_shYT_3
- GSM8943347 HIF2a_RCC4_Parental
- GSM8943348 HIF2a_RCC4_shYT
- GSM8943349 HIF2a_A498_Parental
- GSM8943350 HIF2a_A498_shYT
- GSM8943351 JUNB_786O_Parental_1
- GSM8943352 JUNB_786O_shJUN_1
- GSM8943353 JUNB_786O_Parental_2
- GSM8943354 JUNB_786O_shHIF2_2
- GSM8943355 JUNB_786O_Parental_3
- GSM8943356 JUNB_786O_shYT_3
+ 20 more — browse all 60 samples with per-sample file links →
- GSE17895 Somatic Mutation Screen of Clear Cell RCC 160 samples same disease briefing
- GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing
- GSE22316 PBRM1 Knockdown in RCC Cell Lines 89 samples same disease briefing
- GSE216495 Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma 36 samples same disease briefing
- GSE19982 Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma 30 samples same disease briefing
- GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing
- GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing
- GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.